PT  - JOURNAL ARTICLE
AU  - De, T.
AU  - Zhang, H.
AU  - Alarcon, C.
AU  - Lec, B.
AU  - Avitia, J.
AU  - Smithberger, E.
AU  - Chen, Chuyu
AU  - Horvath, M.
AU  - Kwan, S.
AU  - Young, M.
AU  - Adhikari, S.
AU  - Kwon, J. H.
AU  - Pacheco, J.
AU  - Jarvik, G.P.
AU  - Wei, W.
AU  - Mentch, F.
AU  - Hakonarson, H.
AU  - Sleiman, P.
AU  - Gordon, A.S.
AU  - Harley, J.
AU  - Linneman, J. G.
AU  - Hebbring, S.
AU  - Parisiadou, L.
AU  - Perera, M. A.
TI  - Genetic association of primary non-response to Anti-TNFα therapy in patients with Inflammatory Bowel Disease
AID  - 10.1101/2020.06.23.20138495
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.06.23.20138495
4099  - http://medrxiv.org/content/early/2020/07/22/2020.06.23.20138495.short
4100  - http://medrxiv.org/content/early/2020/07/22/2020.06.23.20138495.full
AB  - Background & Aims Primary non-response (PNR) to anti-tumor necrosis factor-α (TNFα) biologics is a serious concern in patients with inflammatory bowel disease (IBD). We aimed to identify the genetic variants associated with PNR.Methods Patients were recruited from outpatient GI clinics and PNR was determined using both clinical and endoscopic findings. A case-control genome-wide association study was performed in 589 IBD patients and associations were replicated in an independent cohort of 293 patients. Effect of the associated variant on gene expression and TNFα secretion was assessed by cell-based assays. Pleiotropic effects were investigated by Phenome-wide Association Study (PheWAS).Results We identified rs34767465 as associated with PNR to anti-TNF-α therapy (OR:2.07, 95%CI:1.46-2.94, p=2.43×10−7, [Replication OR:1.8, 95%CI:1.04-3.16, p=0.03]). rs34767465 is a multiple-tissue expression quantitative trait loci for FAM114A2. Using RNA-sequencing and protein quantification from HapMap lymphoblastoid cell lines (LCLs), we found a significant decrease in FAM114A2 mRNA and protein expression in both heterozygous and homozygous genotypes when compared to wild type LCLs. TNF-α secretion was significantly higher in THP-1 cells [differentiated into macrophages] with FAM114A2 knockdown versus controls. Immunoblotting experiments showed that depletion of FAM114A2 impaired autophagy related pathway genes suggesting autophagy mediated TNF-α secretion as a potential mechanism. PheWAS showed rs34767465 was associated with comorbid conditions found in IBD patients (derangement of joints [p=2.3×10−4], pigmentary iris degeneration [p=5.1×10−4], diverticulum of esophagus [p=6.3×10−4]).Conclusion We identified a variant rs34767465 associated with PNR to anti-TNFα biologics, which increases TNFα secretion through mechanism related to autophagy. rs34767465 may also explain the comorbidities associated with IBD.Competing Interest StatementThe authors have declared no competing interest.Funding StatementMAP received pilot funding from the Digestive Disease Research Core Centers (NIDDK P30DK42086). Genotyping service was provided by PGRN-CGM International Collaborative Studies. JH received UO1 funding from NHGRI (HG011172) and RO1 from NIAID (AI130830). LP received funding from Michael J. Fox Foundation for Parkinsons Research and RO1 from NIH (NS097901)Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the Institutional Review Board of University of Chicago [IRB No: 00203816].All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData are available on reasonable request. All data relevant to the study are included in the article.